The number of shares to be allocated is based on a defined target level for  each position level. No payments for any vesting are made by the participants. If all KPIs are reached on target level, a total of approximately 2.5m shares will vest from the programme with a total value based on the current share price amounting to EUR 29m (value at close of Nasdaq Copenhagen on 07 April 2025).

The actual number of restricted performance shares available for distribution may range between 0 and 150 percent of the target level and is determined by Vestas' performance in the financial year 2027. The maximum allocation of shares under the programme in total is approximately 3.75m shares.

The number of shares allocated to the registered members of the Executive Management (the CEO and CFO), will follow the guidelines as described in Vestas' Remuneration Policy. For 2025, the CEO will be allotted a target allocation of 245,000 shares and the CFO will be allotted a target allocation of 78,000 shares for target achievement. The 2025 target number of shares corresponds to approx. 156 percent of the annual base salary for the CEO and 103 percent of the   annual base salary for the CFO. The value of the actual number of shares vesting for the CEO and CFO will be capped at a maximum of 300 percent of the annual base salary at time of vesting.

For the purpose of attraction and retention, additional shares, corresponding to a smaller portion (as determined by the Board of Directors) of the total number of shares available under the programme, can be allocated in extraordinary cases, serving as an alternative to cash at sign-on or as retention.

The additional allocations are not adjusted for performance and can be allocated to selected participants on top of their standard allocation. These restricted shares will follow the vesting period and all other terms and conditions for the performance share incentives. The selected individuals and the number of shares will be approved by Executive Management and reported to the Nomination & Compensation Committee. For members of Executive Management to be allocated such additional non-performance-based shares, approval from the Nomination & Compensation Committee will be required, and any allocation to the CEO and CFO will be reported as part of the remuneration report presented at the Annual General Meeting.